The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Open accessAbstract
OBJECTIVE: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study. METHODS: In total, 630 patients with stable MS with muscle spasticity from 33 UK centres were randomised to receive oral Delta(9)-tetrahydrocannabinol (Delta(9)-THC), cannabis extract, or placebo in the main 15 week CAMS study. The primary outcome was change in the Ashworth spasticity scale. Secondary outcomes were the Rivermead Mobility Index, timed 10 metre walk, UK Neurological Disability Score, postal Barthel Index, General Health Questionnaire-30, and a series of nine category rating scales. Following the main study, patients were invited to continue medication, double blinded, for up to 12 months in the follow up study reported here. RESULTS: Intention to treat analysis of data from the 80% of patients followed up for 12 months showed evidence of a small treatment effect on muscle spasticity as measured by change in Ashworth score from baseline to 12 months (Delta(9)-THC mean reduction 1.82 (n = 154, 95% confidence interval (CI) 0.53 to 3.12), cannabis extract 0.10 (n = 172, 95% CI -0.99 to 1.19), placebo -0.23 (n = 176, 95% CI -1.41 to 0.94); p = 0.04 unadjusted for ambulatory status and centre, p = 0.01 adjusted). There was suggestive evidence for treatment effects of Delta(9)-THC on some aspects of disability. There were no major safety concerns. Overall, patients felt that these drugs were helpful in treating their disease. CONCLUSIONS: These data provide limited evidence for a longer term treatment effect of cannabinoids. A long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study reported that 74% of the patients in the placebo group, versus 45% of the patients receiving cannabinoid-based medications, cited a lack of benefit derived from experimental medication as the reason for discontinuation of the trial.145”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [145]
In the citing paper
“A one year double-blind, placebo-controlled follow up study in MS patients demonstrated improved symptoms of pain, spasms, spasticity, sleep, shakiness, energy level, and tiredness following administration of either dronabinol or Cannador®.145”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smithson, M. J. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
Panikashvili, D., Simeonidou, C., Ben‐Shabat, S., Hanuš, L., Breuer, A., Mechoulam, R., & Shohami, E. (2001) · Nature · doi:10.1038/35097089 · Cited by 752
Skaper, S. D., Buriani, A., Toso, R. D., Petrelli, L., Romanello, S., Facci, L., & Leon, A. A. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3984 · Cited by 379
ASV (1990) · Thorax · doi:10.1136/thx.45.2.160-a · Cited by 356
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
Pryce, G., Ahmed, Z., Hankey, D. J. R., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C. A., Petzold, A., Thompson, A. J., Giovannoni, G., et al. (2003) · Brain · doi:10.1093/brain/awg224 · Cited by 345
The perceived effects of smoked cannabis on patients with multiple sclerosis.
Consroe, P., Musty, R., Rein, J. A., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 329
Wiles, C. M. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.2.174 · Cited by 222
Neuroprotection in Parkinson's disease: Clinical trials
Stocchi, F., & Olanow, C. W. (2003) · Annals of Neurology · doi:10.1002/ana.10488 · Cited by 102
Flagged first, then by citations
Research works printed but not linked: 2
- Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta9- tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci SA 1998;95:8268-73.
- Riazi A, Fox P, Vickery J, et al. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Multiple Sclerosis 2003;9:S151.
Cited by
Sorted by citations
Items 101–200 of 336
Cannabis and pain: a scoping review
Pantoja‐Ruiz, C., Restrepo-Jiménez, P., Castañeda‐Cardona, C., Ferreirós, A., & Rosselli, D. (2021) · Brazilian Journal of Anesthesiology (English Edition) · doi:10.1016/j.bjane.2021.06.018 · Cited by 77
Cannabinoid control of neuroinflammation related to multiple sclerosis
Baker, D., Jackson, S. J., & Pryce, G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707458 · Cited by 69
Rabgay, K., Waranuch, N., Chaiyakunapruk, N., Sawangjit, R., Ingkaninan, K., & Dilokthornsakul, P. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.07.015 · Cited by 69
Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol
Madden, K., Tanco, K. C., & Bruera, E. D. (2020) · PEDIATRICS · doi:10.1542/peds.2019-3256 · Cited by 67
Giacoppo, S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0131-8 · Cited by 62
Role of Cannabinoids in Pain Management
Russo, E. B., & Hohmann, A. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1560-2_18 · Cited by 62
Developmental Effects of Cannabinoids on Zebrafish Larvae
Akhtar, M. T., Ali, S., Rashidi, H., van der Kooy, F., Verpoorte, R., & Richardson, M. K. (2013) · Zebrafish · doi:10.1089/zeb.2012.0785 · Cited by 59
The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12050682 · Cited by 58
Targeting the endocannabinoid system in treating brain disorders
Bahr, B. A., Karanian, D. A., Makanji, S. S., & Makriyannis, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.4.351 · Cited by 57
Fowler, C. J. (2006) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2006.00442.x · Cited by 58
An Overview of Pharmacologic Management of Chronic Pain
Beal, B. R., & Wallace, M. S. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.08.006 · Cited by 55
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Inglet, S., Winter, B., Yost, S. E., Entringer, S., Lian, A., Biksacky, M., Pitt, R. D., & Mortensen, W. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020930189 · Cited by 56
Oshaghi, M., Kourosh‐Arami, M., & Roozbehkia, M. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06413-0 · Cited by 60
Jeddi, H. M., Busse, J. W., Sadeghirad, B., Levine, M., Zoratti, M. J., Wang, L., Noori, A., Couban, R., & Tarride, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2022-068182 · Cited by 62
Maayah, Z. H., Takahara, S., Ferdaoussi, M., & Dyck, J. R. B. (2020) · Inflammation Research · doi:10.1007/s00011-020-01341-1 · Cited by 55
Velayudhan, L., McGoohan, K., & Bhattacharyya, S. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003524 · Cited by 56
Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review
Furgiuele, A., Cosentino, M., Ferrari, M., & Marino, F. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-09982-7 · Cited by 59
Pryce, G., Riddall, D., Selwood, D. L., Giovannoni, G., & Baker, D. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9575-8 · Cited by 51
The central cannabinoid receptor type-2 (CB2) and chronic pain
Shang, Y.-C., & Tang, Y. (2016) · International Journal of Neuroscience · doi:10.1080/00207454.2016.1257992 · Cited by 51
Zhang, H., Hilton, D. A., Hanemann, C. O., & Zajicek, J. (2011) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00477.x · Cited by 50
Therapeutic Potential of Cannabinoid-Based Drugs
Klein, T., & Newton, C. A. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_43 · Cited by 49
Examining the relationship between fatigue and cognition after stroke: A systematic review
Lagogianni, C., Thomas, S., & Lincoln, N. B. (2016) · Neuropsychological Rehabilitation · doi:10.1080/09602011.2015.1127820 · Cited by 50
Therapeutic potential of CB2 targeting in multiple sclerosis
Docagne, F., Mestre, L., Loría, F., Hernangómez, M., Correa, F., & Guaza, C. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.185 · Cited by 28
Effective treatment of spasticity using dronabinol in pediatric palliative care
Kuhlen, M., Hoell, J. I., Gagnon, G., Balzer, S., Oommen, P. T., Borkhardt, A., & Janßen, G. (2016) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.07.021 · Cited by 46
Complementary and Alternative Medicine and Multiple Sclerosis
Bowling, A. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.12.006 · Cited by 43
Turri, M., Teatini, F., Donato, F., Zanette, G., Tugnoli, V., Deotto, L., Bonetti, B., & Squintani, G. M. (2018) · Medicines · doi:10.3390/medicines5030059 · Cited by 43
Rovare, V. P. D. [., Magalhães, G. P. A., Jardini, G. D. A., Beraldo, M. L., Gameiro, M. O., Agarwal, A., Luvizutto, G. J., Ramos, L. D. P., Camargo, S. E. A., de Oliveira, L. D., et al. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.08.010 · Cited by 42
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
Mecha, M., Carrillo-Salinas, F. J., Feliú, A., Mestre, L., & Guaza, C. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00034 · Cited by 43
Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review
Farzaei, M. H., Shahpiri, Z., Bahramsoltani, R., Moghadamnia, M., Najafi, F., & Rahimi, R. (2017) · CNS Drugs · doi:10.1007/s40263-017-0466-4 · Cited by 41
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis
Pryce, G., & Baker, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_7 · Cited by 40
Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial
Zadikoff, C., Wadia, P. M., Miyasaki, J. M., Chen, R. E., Lang, A. E., So, J., & Fox, S. H. (2011) · Basal Ganglia · doi:10.1016/j.baga.2011.04.002 · Cited by 40
Medical marijuana in neurology
Benbadis, S. R., Sanchez‐Ramos, J., Bozorg, A. M., Giarratano, M., Kalidas, K., Katzin, L. W., Robertson, D. S., Vu, T., Smith, A., & Zesiewicz, T. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.985209 · Cited by 40
Cannabis-based medicines in multiple sclerosis – A review of clinical studies
Rog, D. J. (2010) · Immunobiology · doi:10.1016/j.imbio.2010.03.009 · Cited by 39
Cannabinoids for the treatment of spasticity
Nielsen, S., Murnion, B. P., Campbell, G., Young, H., & Hall, W. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14165 · Cited by 39
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
Leussink, V. I., Husseini, L., Warnke, C., Broussalis, E., Hartung, H., & Kieseier, B. C. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612453972 · Cited by 39
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
Pryce, G., & Baker, D. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712801661310 · Cited by 39
Abd‐Nikfarjam, B., Dolati‐Somarin, A., Rahimi, V. B., & Askari, V. R. (2023) · BioFactors · doi:10.1002/biof.1936 · Cited by 37
Use of Cannabinoids for Spasticity and Pain Management in MS
Chohan, H., Greenfield, A. L., Yadav, V., & Graves, J. S. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0385-y · Cited by 36
Cannabis for Pain and Headaches: Primer
Kim, P. S., & Fishman, M. A. (2017) · Current Pain and Headache Reports · doi:10.1007/s11916-017-0619-7 · Cited by 36
Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
Kapoor, R. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227034.85576.16 · Cited by 35
Reassessment of the role of cannabinoids in the management of pain
Beaulieu, P., & Ware, M. (2007) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3282efd175 · Cited by 34
Lynch, M. E., Young, J., & Clark, A. J. (2006) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.05.016 · Cited by 34
Ponsonby, A., Lucas, R. M., Dear, K. B. G., van der Mei, I. A. F., Taylor, B. V., Chapman, C., Coulthard, A., Dwyer, T., Kilpatrick, T. J., McMichael, A. J., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513483887 · Cited by 34
Cannabis and multiple sclerosis
Fragoso, Y. D., Carrá, A., & Macias, M. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1776610 · Cited by 34
Cabranes, A., Pryce, G., Baker, D., & Fernández‐Ruíz, J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.001 · Cited by 34
Single center experience with medical cannabis in Gilles de la Tourette syndrome
Thaler, A., Arad, S., Schleider, L. B., Knaani, J., Taichman, T., Giladi, N., & Gurevich, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.004 · Cited by 33
Italian consensus on treatment of spasticity in multiple sclerosis
Comı, G., Solari, A., Leocani, L., Centonze, D., Otero‐Romero, S., & the Italian Consensus Group on treatment of spasticity in multiple sclerosis (2019) · European Journal of Neurology · doi:10.1111/ene.14110 · Cited by 33
Cannabinoids in the management of spasticity associated with multiple sclerosis
Bifulco, M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3208 · Cited by 32
Cannabinoids for Neuropathic Pain
Fine, P. G., & Rosenfeld, M. J. (2014) · Current Pain and Headache Reports · doi:10.1007/s11916-014-0451-2 · Cited by 32
Cannabis: extracting the medicine
Hazekamp, A. (2007) · Leiden Repository (Leiden University) · Cited by 32
Re-Branding Cannabis: The Next Generation of Chronic Pain Medicine?
Carter, G. T., Javaher, S. P., Nguyen, M. H. V., Garrett, S. B., & Carlini, B. H. (2014) · Pain Management · doi:10.2217/pmt.14.49 · Cited by 33
Cannabis in End-of-Life Care: Examining Attitudes and Practices of Palliative Care Providers
Luba, R. R., Earleywine, M., Farmer, S. L., & Slavin, M. N. (2018) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2018.1462543 · Cited by 31
Baker, D., Pryce, G., Jackson, S. J., Bolton, C., & Giovannoni, G. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2011.11.001 · Cited by 31
Targeting the Endocannabinoid System in Psychiatric Illness
Katzman, M. A., Furtado, M., & Anand, L. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000581 · Cited by 30
Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders
Noel, C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.029 · Cited by 29
High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells
Widmer, M., Hanemann, C. O., & Zajicek, J. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21757 · Cited by 28
Perspectives on marijuana use and effectiveness
Cofield, S. S., Salter, A. R., Tyry, T. M., Crowe, C., Cutter, G., Fox, R. J., & Marrie, R. A. (2017) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000383 · Cited by 27
Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?
Rodríguez, J., Munteis, E., Carreño, M., Blanco, Y., Roquer, J., Abanades, S., Graus, F., & Saiz, A. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.037 · Cited by 25
Buccellato, E., Carretta, D., Utan, A., Cavina, C., Speroni, E., Grassi, G., Candeletti, S., & Romualdi, P. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.11.035 · Cited by 24
Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective
Karst, M., & Wippermann, S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802691951 · Cited by 24
Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal
Weinkle, L. J., Domen, C. H., Shelton, I. T., Sillau, S., Nair, K. V., & Álvarez, E. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.11.022 · Cited by 25
Cannabinoids and Neurodegenerative Diseases
Romero, J., & Martínez-Orgado, J. A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824589 · Cited by 24
Complementary and alternative medicine: Is there a role in multiple sclerosis?
Yadav, V., & BOURDETTE, D. N. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0014-y · Cited by 21
Yadav, V., & Narayanaswami, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.011 · Cited by 21
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
Gado, F., Digiacomo, M., Macchia, M., Bertini, S., & Manera, C. (2018) · Medicines · doi:10.3390/medicines5030091 · Cited by 21
Cannabinoid System and Neuroinflammation: Implications for Multiple Sclerosis
Correa, F., Docagne, F., Mestre, L., Loría, F., Hernangómez, M., Borrell, J. I., & Guaza, C. (2007) · NeuroImmunoModulation · doi:10.1159/000110644 · Cited by 21
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis
Nandoskar, A., Raffel, J., Scalfari, A., Friede, T., & Nicholas, R. S. (2017) · Drugs · doi:10.1007/s40265-017-0726-0 · Cited by 21
Johal, H. S., Vannabouathong, C., Chang, Y., Zhu, M. T., & Bhandari, M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20937968 · Cited by 20
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
Smith, P. F. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5974 · Cited by 20
Role of Cannabinoids in the Management of Neuropathic Pain
Fontelles, M. I. M., & Goicoechea, C. (2008) · CNS Drugs · doi:10.2165/00023210-200822080-00003 · Cited by 20
Cannabinoids in Health and Disease
Meccariello, R., & Chianese, R. (2016) · InTech eBooks · doi:10.5772/61595 · Cited by 22
A Scoping Review on Clinical Trials of Pain Reduction With Cannabis Administration in Adults
Haleem, R., & Wright, R. C. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4210 · Cited by 20
Deutsch, S. I., Rosse, R. B., Connor, J. M., Burket, J. A., Murphy, M. E., & Fox, F. J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016564 · Cited by 20
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances
Smith, P. F. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.9.1157 · Cited by 20
McCarberg, B. H. (2007) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v21n03_04 · Cited by 21
Quais são e pra que servem os medicamentos à base de Cannabis?
Pamplona, F. A. (2014) · Revista da Biologia · doi:10.7594/revbio.13.01.05 · Cited by 20
“Variedades de Bedrocan® já foram estudadas com resultados positivos em dor crônica, glaucoma, esclerose múltipla (Zajicek et al., 2005, Nucci et al., 2008, Ware et al., 2010).”
BackgroundCannabinoids, multiple sclerosis and neuroprotection
de Lago, E., Gómez‐Ruíz, M., Moreno‐Martet, M., & Fernández‐Ruíz, J. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.42 · Cited by 19
Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence
Wright, S. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0003-4 · Cited by 19
The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia
Gerdeman, G. L., & Fernández‐Ruíz, J. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_21 · Cited by 19
Tyree, G. A., Sarkar, R. R., Bellows, B. K., Ellis, R. J., Atkinson, J. H., Marcotte, T. D., Wallace, M. S., Grant, I., Shi, Y., Murphy, J. D., et al. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0027 · Cited by 17
The Pharmacotherapy of Chronic Pain
Lynch, M. E. (2008) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2008.04.001 · Cited by 18
Notcutt, W. G. (2012) · Primary Health Care Research & Development · doi:10.1017/s1463423612000333 · Cited by 18
Polymorphisms of the cannabinoid 1 receptor gene and cognitive impairment in multiple sclerosis
Woolmore, J. A., Stone, M., Holley, S. L., Jenkinson, P. M., W.A., I. G. A. K. C. A., Jones, P., Fryer, A. A., Strange, R. C., Stephens, R., Langdon, D. W., et al. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507081343 · Cited by 17
Kim, J. S., Soto‐Díaz, K., Bingham, T. W., Steelman, A. J., & Das, A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.102886 · Cited by 16
Sutton, I. R., & Daeninck, P. J. (2006) · PubMed · Cited by 16
Open-Label, Add-on Study of Tetrahydrocannabinol for Chronic Nonmalignant Pain
Haroutounian, S., Rosen, G., Shouval, R., & Davidson, E. M. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280802251215 · Cited by 16
Palmieri, B., Laurino, C., & Vadalà, M. (2019) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12514 · Cited by 16
Sîrbu, C. A., Georgescu, R., Pleşa, C., Păunescu, A., Ţânţu, M. M., Nicolae, A. C., Caloianu, I., & Mitrică, M. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001568 · Cited by 15
Hazekamp, A., & Pappas, G. J. (2014) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199662685.003.0017 · Cited by 15
Cannabinoids for Pain Management
Thaler, A., Gupta, A., & Cohen, S. P. (2011) · Advances in psychosomatic medicine · doi:10.1159/000324070 · Cited by 14
Cogan, P. S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1612743 · Cited by 14
Cannabinoid-Based Medicines and Multiple Sclerosis
Manera, C., & Bertini, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_8 · Cited by 15
Hasseldam, H., & Johansen, F. F. (2010) · NeuroImmunoModulation · doi:10.1159/000290041 · Cited by 14
Potencial uso terapéutico de cannabis
Marcia Avello, L., Pastene, E., Pola Fernández, R., & Mariángel, P. C. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017000300010 · Cited by 14
U.S. Policy Responses to Calls for the Medical Use of Cannabis.
Hall, W. (2015) · PubMed Central · Cited by 13
Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation
Radke, P. M., Mokhtarzadeh, A., Lee, M. S., & Harrison, A. R. (2017) · Neuro-Ophthalmology · doi:10.1080/01658107.2017.1318150 · Cited by 13
The role of complementary and alternative medicine in therapy of multiple sclerosis.
Kes, V. B., Cesarik, M., Matovina, L. Z., Zavoreo, I., Čorić, L., Drnasin, S., & Demarin, V. (2013) · PubMed · Cited by 13
Pharmacological treatment of tremor in multiple sclerosis; a systematic review
Pourmohammadi, A., Riahi, R., Hosseini, S. M., & Adibi, I. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103722 · Cited by 12
Multiple Sclerosis, Cannabinoids, and Cognition
Papathanasopoulos, P., Messinis, L., Lyros, E., Kastellakis, A., & Panagis, G. (2008) · Journal of Neuropsychiatry · doi:10.1176/jnp.2008.20.1.36 · Cited by 12
Metadata
- Authors
- Zajicek, J. P.
- Affiliations
- University of Plymouth (GB)
- Corresponding author
- Zajicek, J P
- ORCID
- Zajicek, J P
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2005-12-01
- Volume
- 76
- Issue
- 12
- Pages
- 1664-1669
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC1739436
- OpenAlex
- W2031114852
- Cited by
- 335
- References
- 11
- Citations by year
- 2026: 5 · 2025: 23 · 2024: 16 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 15 · 2019: 12 · 2018: 16 · 2017: 20 · 2016: 10 · 2015: 19 · 2014: 22 · 2013: 16 · 2012: 20
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- multiple sclerosis, cannabinoids, delta-9-tetrahydrocannabinol, cannabis extracts, spasticity, long-term safety, disability, mobility (physical function), spasticity management
- MeSH terms
- Administration, Oral, Adolescent, Adult, Cannabis, Double-Blind Method, Female, Persons with Disabilities, Humans, Male, Middle Aged, Multiple Sclerosis, Placebos, Plant Extracts, Severity of Illness Index, Treatment Outcome, Analgesics, Non-Narcotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
